Back to publication

Clinical Trial on the Effects of Vitamin D Supplementation on Metabolic Profiles in Diabetic Hemodialysis

Assessed by RV008 · PhD Candidate

Assessed on 16 Nov 2025

OverallReviewer's overall integrity assessment, derived from all research questions Serious concerns

DOI 10.1055/s-0043-119221 (opens in new tab)

Resource ripekg:research-integrity-assessment/RIPEA188DF79DAC4D30E2

5 Research Questions · 45 Evidence Items

Q1.1 — Does the study have an associated retraction?

Automated Assessment:Assessment produced by the automated systemNo
Human Assessment:Assessment by a domain expert reviewer, informed by AI resultsYes

Rationale: Confirmed by going to journal's website

Supporting Evidence (1)

Retraction NoticeSource: Retraction Watch database

Long-Term Vitamin D Supplementation Affects Metabolic Status in Vitamin D-Deficient Type 2 Diabetic Patients with Coronary Artery Disease

10.1093/jn/nxab073 (opens in new tab)
Journal: The Journal of NutritionPublisher: Oxford AcademicDate: 11 May 2021

RetractionWatch ID:Record identifier in the Retraction Watch database 28369

Rationale: Concerns/Issues About Data;Investigation by Journal/Publisher;Upgrade/Update of Prior Notice(s)

About Authors: Fariba Raygan, Hamid Talari, Ahmad Esmaillzadeh, Fereshteh Bahmani

Q1.2 — Does the study have an associated expression of concern or other relevant post-publication notice?

Automated Assessment:Assessment produced by the automated systemYes
Human Assessment:Assessment by a domain expert reviewer, informed by AI resultsYes

Rationale: No rationale provided

Supporting Evidence (1)

PubPeer ThreadSource: PubPeer.com — post-publication peer review comments

https://pubpeer.com/publications/78448E42EA56FB7500B8A3D0B70110 (opens in new tab)

PubPeer CommentSource: PubPeer.com — a platform for post-publication peer review

Commenter: Andrew GreyDate: 1 May 2021

There are many concerns about the integrity of 172 publications by this research group, including this one. Some of the concerns are published 1. Anaesthesia 2020;75:1683–92, see Supplementary data. This paper is A166 2. Account Res 2020;28:149-61. 3. J Clin Epidemiol 2021;131:22-29. Journals and publishers were notified of these concerns in July 2019. 18 publications have an expression of concern, and 6 have been retracted. To our knowledge there has been no public response about any of the concerns. We think these publications are unreliable

Thread: https://pubpeer.com/publications/78448E42EA56FB7500B8A3D0B70110 (opens in new tab)

Q1.3 — Do other studies by the research team highlight causes for concern?

Automated Assessment:Assessment produced by the automated systemYes
Human Assessment:Assessment by a domain expert reviewer, informed by AI resultsYes

Rationale: No rationale provided

Supporting Evidence (41)

Retraction NoticeSource: Retraction Watch database

Calcium plus vitamin D supplementation influences biomarkers of inflammation and oxidative stress in overweight and vitamin D-deficient women with polycystic ovary syndrome: A randomized double-blind placebo-controlled clinical trial

10.1111/cen.14892 (opens in new tab)
Journal: Clinical EndocrinologyPublisher: WileyDate: 27 Feb 2023

RetractionWatch ID:Record identifier in the Retraction Watch database 43979

Rationale: Investigation by Third Party

About Authors: Fatemeh Foroozanfard, Mehri Jamilian, Teibeh Hashemi, Ahmad Esmaillzadeh, Fereshteh Bahmani

Retraction NoticeSource: Retraction Watch database

Comparison of myo-inositol and metformin on clinical, metabolic and genetic parameters in polycystic ovary syndrome: A randomized controlled clinical trial

10.1111/cen.14889 (opens in new tab)
Journal: Clinical EndocrinologyPublisher: WileyDate: 27 Feb 2023

RetractionWatch ID:Record identifier in the Retraction Watch database 43984

Rationale: Investigation by Third Party

About Authors: Fatemeh Foroozanfard, Mehri Jamilian, Fereshteh Bahmani, Hamidreza Jamilian, Esmat Aghadavod, Faraneh Afshar Ebrahimi

Retraction NoticeSource: Retraction Watch database

Comparison of myo-inositol and metformin on mental health parameters and biomarkers of oxidative stress in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial

10.1080/0167482x.2024.2346385 (opens in new tab)
Journal: Journal of Psychosomatic Obstetrics & GynecologyPublisher: Taylor and FrancisDate: 17 May 2024

RetractionWatch ID:Record identifier in the Retraction Watch database 53693

Rationale: Concerns/Issues About Data;Concerns/Issues about Results and/or Conclusions;Investigation by Journal/Publisher;Investigation by Third Party;Objections by Author(s);Unreliable Results and/or Conclusions;Upgrade/Update of Prior Notice(s)

About Authors: Fatemeh Foroozanfard, Mehri Jamilian, Fereshteh Bahmani, Hamidreza Jamilian, Faraneh Afshar Ebrahimi

Q2.2 — Are there concerns relating to the timing or absence of study registration?

Automated Assessment:Assessment produced by the automated systemNo
Human Assessment:Assessment by a domain expert reviewer, informed by AI resultsNo

Rationale: No rationale provided

Supporting Evidence (2)

Clinical Trial RegistrationSource: Clinical trial registry (e.g. ClinicalTrials.gov, ISRCTN)

Registration ID: IRCT201611155623N92

Registry: IRCT

Registry Link: https://trialsearch.who.int/Trial2.aspx?TrialID=IRCT201611155623N92 (opens in new tab)

Registration Date: 21 Dec 2016

Prospective:Whether the trial was registered before participant recruitment began Yes

Assessment Rationale:How INSPECT-AI determined the prospective registration status by comparing dates Comparison performed at month level. Registration: 2016-12, LLM Recruitment Start: 2016-12. Deemed prospective at month level.

Study Design EvidenceDates and timelines extracted by INSPECT-AI from the publication text

Recruitment Start: 12-2016

Recruitment Start Rationale:INSPECT-AI's reasoning for how it identified the recruitment start date Methods section states 'from December 2016', which is used as the recruitment start date.

Recruitment End: 02-2017

Recruitment End Rationale:INSPECT-AI's reasoning for how it identified the recruitment end date Methods section states 'to February 2017', which is used as the recruitment finish date.

Study End: 02-2017

Study End Rationale:INSPECT-AI's reasoning for how it identified the study end date Methods section states 'from December 2016 to February 2017'. February 2017 is used as the study end date.

Overall — What is the overall integrity assessment of the study?

Automated Assessment:Assessment produced by the automated systemN/A
Human Assessment:Assessment by a domain expert reviewer, informed by AI resultsSerious concerns

Rationale: No rationale provided